tbuckley/cabot-search huggingface dataset:
Oral vinorelbine (NVBO) and gemcitabine (GEM) in elderly patients with advanced non-small-cell lung cancer (NSCLC): A phase II study conducted by the Galician Lung Cancer Group (GLCG)
Authors: J. L. Fírvida, S. Vazquez, C. Grande, L. Leon, M. Salgado, B. Campos, M. Lazaro, R. López, E. Pérez, J. Casal, J. R. Mel
Journal: Journal of Clinical Oncology (2008)

19068 Background: The non-platin doublet GEM-vinorelbine is one of the most effective treatment regimens for elderly patients (PTS) with advanced NSCLC. NVBO has been employed in NSCLC treatment with similar bioavailability and response rates and a more favourable toxicity profile compared to the i.v. form. The GLCG conducted a phase II study to determine the efficacy and safety of NVBO- GEM regimen in elderly patients with advanced NSCLC. The primary objective was response rate (RR). Secondary objectives included time to progression (TTP) overall survival (OS) and toxicity. Methods: Beetween July 2005 and November 2007, 43 chemo-naïve pts aged >70 years, histologically confirmed NSCLC, stage IIIB/IV, ECOG 0–1, measurable lesions according to RECIST criteria and adecuate bone marrow, renal and hepatic function were included. The NVBO-GEM regimen consisted of GEM 1000 mg/m2/i.v., followed by NVBO 60 mg/m2 days 1 and 8 every 3 weeks, for a maximum of 6 cycles. Results: To date, 43 pts were included and 170 cycles were administrated. Male/Female 39/4; median age 78 years (range 71–84), all ECOG 1, 28 squamous cell carcinoma, 11 adenocarcinoma and 4 large cell. Stage IIIB/IV 11/32. 35 pts were evaluable (4 non evaluable and 4 in treatment) for response and 43 for toxicity. The RR was 40%; PR: 40%; SD: 20% and PD: 40%. The median TTP was 4.6 months (95% CI: 2.9–6.2) and the median OS was 9.3 months (95% CI: 6.2–12.4). The main toxicities were anemia grade 3–4 in 4 pts, neutropenia grade 3–4 in 4 and plaquetopenia grade 3 in 2; non- haematological grade 3–4 toxicities included grade 3 asthenia in 3 pts and grade 3 emesis in one. Conclusions: This trial confirms that a NVBO-GEM regimen is effective and well tolerated in elderly pts with advanced NSCLC. No significant financial relationships to disclose.
A Retrospective Study on Safety, Efficacy and Cost of the Chemo-Mobilization for Patients Planned to Undergo Autologous Hematopoietic Stem Cell Transplant: The Secom Study
Authors: Surapol Issaragrilsil, Yeow-Tee YT Goh, Anskar Y.H. Leung, S Fadilah S Abdul Wahid, Hwai Tzeng Cheng
Journal: Blood (2014)
Abstract 17791: Predictors of Left Ventricular Thrombus Following ST-Segment Elevation Myocardial Infarction: Findings From the Duke Databank of Cardiovascular Disease and the Duke Echocardiography Databank
Authors: Adam M Garber, Robert J Mentz, Linda K Shaw, Hussein R Al-Khalidi, Mona Fiuzat, Christopher O’Connor, Eric J Velazquez
Journal: Circulation (2013)

Background: The clinical characteristics predictive of left ventricular thrombus (LVT) formation after ST-segment elevation myocardial infarction (STEMI) are not well defined in the contemporary er...
Tubular stomach versus whole stomach for esophagectomy through cervico-thoraco-abdominal approach: a comparative clinical study of anastomotic leakage
Authors: Chao Sun, Wei-ping Shi, Yu-sheng Shu, Hong-can Shi, Shi-chun Lu, Kang Wang
Journal: BMJ (2012)

A total of 850 patients undergoing the 3-field esophagectomy were retrospectively recruited and divided into tubular stomach reconstruction group (n =453) and whole stomach reconstruction group (n =397).They underwent esophagectomy through right thorax,left cervical part,abdominal triple incisions and esophageal reconstruction by hand-sewn two-layer anastomosis.In comparison with whole stomach,esophageal reconstruction with tubular stomach had a lower incidence of anastomotic leakage,less manifestation of intrathoracic syndrome and less occurrence of reflux esophagitis (P ＜ 0.05).However,the incidence of anastomotic stricture showed no significant difference between two groups (P ＞ 0.05).It suggests that,for esophageal cancer patients undergoing the 3-field esophagectomy,tubular stomach is better than whole stomach for esophageal reconstruction as reflected by reduced occurrences of postoperative anastomotic leakage,intrathoracic syndrome and reflux esophagitis.

Key words: 
Thoracic surgery, side effects; Esophageal cancer
Association Between Nonstenosing Carotid Artery Plaque on MR Angiography and Acute Ischemic Stroke
Authors: Ajay Gupta, Gino Gialdini, Ashley E. Giambrone, Michael P. Lerario, Hediyeh Baradaran, Babak B. Navi, Randolph S. Marshall, Costantino Iadecola, Hooman Kamel
Journal: JACC. Cardiovascular imaging (2016)
Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?
Authors: Divi Cornec, Sebastian Costa, Valérie Devauchelle-Pensec, Laurent Chiche, Alain Saraux, Jacques-Olivier Pers
Journal: Annals of the Rheumatic Diseases (2016)

worse outcomes after rituximab in patients with primary Sjögren's syndrome?
MicroRNAs that underlie response to salvage chemotherapy in ovarian cancer
Authors: T. P. Boren, S. Cui, G. Chan, H. Dressman, J. M. Lancaster
Journal: Journal of Clinical Oncology (2007)

10542 Background: MicroRNAs (miRNAs) are non-protein coding, endogenous, small RNAs that can bind complementary mRNA to modulate gene expression and protein translation. Recent studies indicate that miRNAs may be mechanistically involved in ovarian cancer chemosensitivity and may play an important role in the development of chemoresistance. The objective of the current study was to explore the role of miRNAs in the response of platinum-resistant recurrent or persistent ovarian cancer to salvage chemotherapy. Methods: MicroRNA was extracted from 16 ovarian cancer cell lines. All samples were hybridized to a miRNA array that contained Ambion and Invitrogen probe sets. In parallel, the 16 ovarian cancer cell lines were treated with Doxorubicin, Topotecan, Paclitaxel, Docetaxel, and Gemcitabine, and their response to treatment evaluated using proliferation assays. Logistic regression analysis was used to identify miRNAs associated with responsiveness to individual chemotherapeutic agents. Results: Linear regression analysis identified a total of 39 miRNAs significantly associated with salvage chemotherapy responsiveness. Sixteen miRNAs were associated with response to Doxorubicin, 18 associated with response to Topotecan, 2 associated with response to Docetaxel, 9 associated with response to Paclitaxel, and 11 associated with response to Gemcitabine (p&lt;0.05). Ten miRNAs were associated with more than one chemotherapy (miR-126, miR-199a, miR-202 [Doxorubicin, Topotecan, Gemcitabine], miR-26a, miR-320 [Doxorubicin, Topotecan], miR-181b [Doxorubicin, Topotecan, Paclitaxel], 181a [Topotecan, Gemcitabine, Adriamycin, Paclitaxel], miR-99b [Doxorubicin, Paclitaxel, Docetaxel], miR-31 [Docetaxel, Paclitaxel], miR-339 [Doxorubicin, Gemcitabine]). Conclusion: We have identified miRNAs that may influence ovarian cancer responsiveness to salvage chemotherapy. Ten of the miRNAs were associated with chemosensitivity to more than one drug. These miRNAs may regulate common determinants of chemoresistance and may also serve as novel therapeutic targets for patients with chemoresistant ovarian cancer. Further studies are warranted to validate these results. No significant financial relationships to disclose.
The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer.
Authors: T. Kim, H. Lee, S. Han, D. Oh, S. Im, Y. Bang
Journal: Journal of Clinical Oncology (2010)

1071 Background: Recently, the role of platinum is being highlighted in triple-negative (TN) metastatic breast cancer (MBC). However, the role of platinum has not been focused according to hormone receptor (HR) and HER2 status. We conducted this study to analyze the benefits of platinum-containing chemotherapy (PCC) according to HR and HER2 status in MBC. Methods: We consecutively enrolled MBC patients who received PCC between 2001 and 2008. The benefits of PCC were evaluated by RR, DCR, PFS, and OS. The comparison between triple-negative (TNBC) and non-TNBC was done according to the timing of PCC introduction (as first- to third-line vs >fourth-line) and the number of metastatic site (1-2 vs. >3), the benefits of PCC and so on. Results: A total of 158 patients (pts) were enrolled (HR [+]: 68 pts [43%], HER-2 [+] :17 pts [11%]). Sixty two pts (39%) had TNBC and 90 pts (57%) had non-TNBC. 67 pts received the PCC as a first- through third-line palliative treatment and the number of metastatic site was 1-2 in 91 pts at the time of initiation of PCC. The RR, DCR, PFS, OS for all 158 pts was 26.1% (95% CI: 19.2-32.9), 56.3% (48.5-64.0), 4.4 months (3.6-5.2), 10.7 months (8.6-12.8). According to triple-negativity, even though the proportion of the pts receiving PCC as first- to third-line treatment was higher in TNBC compared with non- TNBC (54.8% vs. 34.8%, p=0.015), the proportion of the pts with >3 metastatic sites was higher in TNBC (58.3% vs. 37.3%, p=0.013). There were no differences between TNBC and non-TNBC in terms of RR, DCR, PFS, and OS since the time of initiation of PCC (RR: 27.6% vs. 22.8%, p=0.52, DCR: 50.5% vs. 60.8%, p=0.21, PFS: 4.1 vs. 4.6 months, p=0.90, OS: 10.8 vs. 10.0 months, p=0.69). But, OS from the date of diagnosis of MBC to death was longer in non-TNBC than in TNBC (40.8 vs. 27.8 months, p=0.007). Conclusions: TNBC had more aggressive features than non-TNBC (more metastatic sites at earlier time, shorter OS since MBC). But, TNBC and non-TNBC obtained similar benefits from PCC since the time of introduction of PCC. So, earlier administration of PCC is a considerable strategy in TNBC and PCC has a role not only in TNBC but also in non- TNBC. No significant financial relationships to disclose.
Depression in Lymphocyte Response to General Mitogens by Owl Monkeys Infected With &lt;italic&gt;Herpesvirus saimiri&lt;/italic&gt;&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: W C Wallen, H Rabin, R H Neubauer, J L Cicmanec
Journal: JNCI Journal of the National Cancer Institute (1975)

The effect of Herpesvirus saimiri (HVS) infection on the response of owl monkey lymphocytes to general mitogens was examined during the development of neoplastic disease. The reactivity of the lymphocytes was then correlated with the clinical condition of the infected monkeys and the content of virus rescued from the peripheral blood lymphocytes (PBL). Eight monkeys developed lymphoma which, in six monkeys, was accompanied by lymphocytic leukemia. All animals that died of HVS-induced neoplasia consistently showed a lack of mitogenic response to phytohemagglutinin and concanavalin A. The response to pokeweed mitogen, while always reduced, was generally less markedly affected than the response to the other two mitogens. Lymphocytes from five of the leukemic animals demonstrated an elevated level of spontaneous DNA synthesis in culture late in the disease. This increased spontaneous DNA synthesis tended to correlate with the rescue of HVS from the PBL as demonstrated by the infective center assay. Although mitogenic hyporesponsiveness corresponded with HVS rescue from PBL in six of nine monkeys, the impairment of normal lymphocyte responsiveness sometimes preceded virus recovery.
Correspondence
Authors: C Antzelevitch
Journal: Cardiovascular Research (1997)

A number of studies have described the presence of M cells in the midmyocardial layers of ventricular myŽ . w x ocardium of several species Table 1 1–14 . The M cell is distinguished by the ability of its action potential to prolong disproportionately to other myocardial ventricular cells in response to a slowing of rate andror to agents that prolong action potential duration. The ionic basis for these features of the M cell include the presence a smaller Ž . w x slowly activating delayed rectifier current I 1 as well Ks Ž . w x as a larger late sodium current late I 15 . The unique Na repolarization characteristics of the M cells have yielded some interesting observations relative to our understanding of the electrophysiology, pharmacology and pathophysiology of the ventricles of the heart as well as some new insights into the basis for the electrocardiographic J, T and w x U waves 16 . w x Rodriquez-Sinovas et al. 5 recently confirmed the presence of M cells in the canine heart, but presented evidence for their absence in the porcine heart. Without discounting the value of this fine study, we would like to point out that the work involving the canine tissues was performed using adult dogs, whereas that involving porcine tissues employed pigs 1 to 2 months of age. This difference may be a critically important one in that recent developmental studies indicate that in the dog the M cell is not electrophysiologically distinct until approximately 3 Ž . months of age unpublished observation . The neonatal heart is homogeneous with respect to action potential morphology in the first few days of life. A notched appearance of the action potential gradually appears in epicardial and midmyocardial, but not endocardial, cells in the first few weeks of life due to the accentuation of phase 1, secondary to an increase in the density of the transient Ž . outward current I . Differences in the time of repolarizato tion of phase 3 of the action potential among cells span-
Salvage therapy with topotecan (topo) of heavily pretreated ovarian cancer patients (hpocp)
Authors: G. B. Wcislo, L. Bodnar, M. Miedzinska-Maciejewska, C. Szczylik
Journal: Journal of Clinical Oncology (2004)

5142 Background: Ovarian cancer is a chemosensitive entity. If so, there is an option to treat patients as long is it is possible. Topo is used to be a second-line chemo agent in ovarian cancer. We decided to medicate hpocp with topo as third or more line of chemotherapy. Methods: Hpocp were recorded after chemotherapy with platinum compounds, paclitaxel, doxorubicin. All of them received topo as 30-minute infusion at the dose of 1.5 mg/m2 through 5 consecutive days every 21 days. Toxicity profile was assessed according to NCI CTC and response was measured while met RECIST criteria. Results: Between 2001 and 2003, 18 hpocop were enrolled onto the study and received at least two cycles of topo salvage, median 4, range 2–6. Among the patients who were previously treated, we found 39% (7/18) as platinum-sensitive, 33% (6/18) as platinum-resistant, and 28% (5/18) as platinum-refractory. Ten hpocp of the total number of 18 were monitored to used therapy through fulfilling RECIST criteria: 1/10 (10%) -CR, 2/10 (20%)-PR, 4/10 (40%)-NC, 3/10 (30%). Time to progression of ovarian cancer was 4.6 months mediana, SD+/- 2.5 (range from 2 to 9) and survival 9.7 months mediana, SD +/- 5.6 (range from 2 to 21). Toxicity profile was seen as follow: neutropenia 3rd and 4th grade in 9/18 (50%), anemia 4th grade in 12/18 (66.6%), thrombocytopenia 4th grade in 6/18 (33.3%), and non-hematologic toxicity relied on alopecia 9/18 (50%). We have not observed fatal outcome after topo salvage therapy. Conclusions:Topo has an approval for chemo of patients with ovarian cancer as second-line therapy. The drug is active against ovarian cancer and has non-cumulative toxicity. Therefore, it should be involved in therapy of patients previously heavily pretreated. We think that topo is able to offer ovarian cancer stabilized disease despite pretreatment but reliable management is needed to alleviate hematologic toxicity. No significant financial relationships to disclose.
Contraception and pulmonary embolism.
Authors: Schrogie Jj, Siegel Dg
Journal: New England Journal of Medicine (1971)

A brief comparison of the literature on thromboembolic complications of oral contraceptives is made with the increased mortality rate for nonpregnant females: (3.04 to 3.96 per 1000000) and decreased rate for males recently reported by  Zimmerman Adelson and Ratnoff (New England Journal of Medicine 1970).  Assuming 15% of the population was using oral contraception the increase in females means there is a fourfold increase in risk attributable to oral contraceptives.  Since the number of cases was small tests for significance would  be helpful in interpreting the data.  The data indicate results similar to previously published information on contraceptive pills.  The authors conclusion that the impact of oral contraceptives is not dramatic may be misleading.
Increased Risk for Other Cancers in Addition to Breast Cancer for <i>CHEK2</i>*1100delC Heterozygotes Estimated From the Copenhagen General Population Study
Authors: Charlotte Näslund-Koch, Børge G. Nordestgaard, Stig E. Bojesen
Journal: Journal of Clinical Oncology (2016)

CHEK2 is a cell cycle checkpoint regulator, and the CHEK2*1100delC germline mutation leads to loss of function and increased breast cancer risk. It seems plausible that this mutation could also predispose to other cancers. Therefore, we tested the hypothesis that CHEK2*1100delC heterozygosity is associated with increased risk for other cancers in addition to breast cancer in the general population.We examined 86,975 individuals from the Copenhagen General Population Study, recruited from 2003 through 2010. The participants completed a questionnaire on health and lifestyle, were examined physically, had blood drawn for DNA extraction, were tested for presence of CHEK2*1100delC using Taqman assays and sequencing, and were linked over 1943 through 2011 to the Danish Cancer Registry. Incidences and risks of individual cancer types, including breast cancer, were calculated using Kaplan-Meier estimates, Fine and Gray competing-risks regressions, and stratified analyses with interaction tests.Among 86,975 individuals, 670 (0.8%) were CHEK2*1100delC heterozygous, 2,442 developed breast cancer, and 6,635 developed other cancers. The age- and sex-adjusted hazard ratio for CHEK2*1100delC heterozygotes compared with noncarriers was 2.08 (95% CI, 1.51 to 2.85) for breast cancer and 1.45 (95% CI, 1.15 to 1.82) for other cancers. When stratifying for sex, the age-adjusted hazard ratios for other cancers were 1.54 (95% CI, 1.08 to 2.18) for women and 1.37 (95% CI, 1.01 to 1.85) for men (sex difference: P = .63). For CHEK2*1100delC heterozygotes compared with noncarriers, the age- and sex-adjusted hazard ratios were 5.76 (95% CI, 2.12 to 15.6) for stomach cancer, 3.61 (95% CI, 1.33 to 9.79) for kidney cancer, 3.45 (95% CI, 1.09 to 10.9) for sarcoma, and 1.60 (95% CI, 1.00 to 2.56) for prostate cancer.CHEK2*1100delC heterozygosity is associated with 15% to 82% increased risk for at least some cancers in addition to breast cancer. This information may be useful in clinical counseling of patients with this loss-of-function mutation.
Natural family planning. Deprives poor people of sex [letter]
Authors: Pandit Mj
Journal: BMJ (1993)

In his article on natural family planning (NFP) R.E.J. Ryder makes the controversial assertion that poverty is a   in the success of natural methods of family planning in the developing world and quotes a figure for failure rate similar to that with the combined contraceptive pill.  His article also concludes that NFP  be the family planning  of choice in the Third World.  Although the quoted figures appear to suggest that NFP is effective other factors may contribute to a low failure rate in developing countries.  Most important among these is the low frequency of sexual intercourse in poor couples.  Many poor couples in India (where the reported study was undertaken) live in a single room with their parents their children the husbands siblings and sometimes even the grandparents.  Couples are rarely left by themselves and the situation certainly precludes intercourse on a regular basis.  Poverty may in this way contribute to the low failure rates obtained with NFP methods:  to suggest as Ryder does that poverty is a motivating factor is thus inaccurate.  One important disadvantage of natural methods of family planning is that intercourse is limited to the safe method of the menstrual cycle and therefore in poor couples in the Third World this further reduces the opportunity to have sexual intercourse.  The enjoyment of sex is as important to poor couples in the developing world as it is to couples in the Western world.  The great advantage of the oral contraceptive pill which Ryder does not mention is that it enables poor couples to enjoy sex without risk of pregnancy on the rare occasions that they can. (full text)
The effect of chemotherapeutic agents on chemotaxis and random migration of human leukocytes.
Authors: D K MacFadden, S Saito, W Pruzanski
Journal: Journal of Clinical Oncology (1985)

Chemotherapeutic agents (CTAs) used for treatment of neoplastic and other diseases may influence defense mechanisms of the patient, altering various humoral and cellular immunologic functions. Herein we report the influence of 16 CTAs on random migration and chemotaxis of human polymorphonuclear cells (PMNCs), using two methods, under-agarose migration and double-filter Boyden chambers with 51Cr-PMNCs. Random migration was inhibited by vinblastine only (P less than .01). BCNU and daunorubicin inhibited random migration only when used in high concentrations. In under-agarose migration, only BCNU and vinblastine inhibited chemotaxis (P less than .01) in therapeutic concentrations. Inhibition was also observed when higher concentrations of vincristine were tested. In the Boyden method, marked inhibition of chemotaxis (P less than .01) was caused by BCNU, vinblastine, vincristine, daunorubicin, and doxorubicin. Inhibition of chemotaxis could not be reversed by washing the cells after preincubation. CTAs per se did not have chemoattractant activity. This study shows that some chemotherapeutic agents inhibit random and directed migration of human PMNCs. It also supports the evidence that Boyden chamber method may detect chemotactic abnormalities that escape recognition by the under-agarose migration method. Suppression of locomotion of PMNCs should be taken into consideration in patients treated with CTAs.
Simian Virus 40 (SV40)-Specific Isoelectric Point-4.7-94,000-&lt;italic&gt;M&lt;/italic&gt;&lt;sub&gt;r&lt;/sub&gt; Membrane Glycoprotein: Major Peptide Homology Exhibited With the Nuclear and Membrane-Associated 94,000-&lt;italic&gt;M&lt;/italic&gt;&lt;sub&gt;r&lt;/sub&gt; SV40 T-Antigen in Hamsters&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: R Schmidt-Ullrich, W S Thompson, S J Kahn, M T Monroe, D F Wallach
Journal: JNCI Journal of the National Cancer Institute (1982)

Tryptic peptide maps of electrophoretically purified 94,000-molecular weight (relative) (Mr) nuclear and membrane-associated simian virus 40 (SV40) T-antigens, TN and TM, respectively, were compared to those of the SV40-specific isoelectric point (pI)- 4.7--94,000-Mr plasma membrane component reactive with anti-T-sera from Syrian golden hamsters. Bidimensional thin-layer electrophoresis and chromatography of TN labeled with 125I revealed about 27 tryptic peptides. A similar number of peptides was identified for TM and the pI-4.7--94,000-Mr component. A peptide homology between TN and TM or TN and the pI-4.7-94,000-Mr protein exists and indicates that the previously described pI-4.7--94,000-Mr membrane component represents TM. Only 4 of 27 peptides were labeled when TM was subjected to lactoperoxidase-catalyzed radioiodination from the outer surface of the plasma membrane. One of these TM peptides was metabolically labeled with [14C]glucosamine. The data indicate that TM is partially exposed on the cell surface and represents a glycosylated form of TN. Closely associated with TM is a pI-4.5--55,000-Mr membrane component. This component does not exhibit significant peptide homology with the 94,000-Mr SV40 protein and, therefore, appears to be coded for by the host cell genome.